文献速递淋巴瘤

年轻套细胞淋巴瘤患者的条件生存:欧洲MCL网络随机III期试验结果

Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.
PubMed 文献 · Br J Haematol · 2024-10-23

该研究基于473例年轻套细胞淋巴瘤患者的随机III期试验,比较R-CHOP与交替R-CHOP/R-DHAP方案后自体移植的条件总生存和无失败生存。R-CHOP组5年条件生存随已生存时间延长而升高(生存1年和7年后分别为72%和81%),R-CHOP/R-DHAP组则稳定(77%和78%)。

要点

  • R-CHOP组5年条件生存从生存1年后的72%升至生存7年后的81%。
  • R-CHOP/R-DHAP组5年条件生存稳定在77%至78%。
  • 治疗失败患者生存显著劣于持续缓解者,与已生存时间无关。

核心结论

  • 结果可为年轻MCL患者提供动态预后和个体化咨询,并强调高效一线治疗对改善生存的重要性。

研究设计与样本

  • 随机III期试验,纳入473例年轻套细胞淋巴瘤患者,比较R-CHOP与交替R-CHOP/R-DHAP免疫化疗后自体移植。
  • 采用条件Kaplan-Meier法和Cox回归,评估已生存1-8年患者的后续生存,考虑MIPI、Ki-67和治疗失败状态。

主要发现

  • R-CHOP组5年条件生存从生存1年后的72%升至生存7年后的81%。
  • R-CHOP/R-DHAP组5年条件生存为生存1年后的77%和生存7年后的78%,随时间稳定。
  • MIPI的预后价值在R-CHOP组3年后减弱,在R-CHOP/R-DHAP组保持不变。
  • 治疗失败患者生存显著劣于持续缓解者,与已生存时间无关。
  • 患者缓解时间越长,无治疗失败生存时间越长。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

During a fatal disease, patients often request updated information on their prognosis. After patients have already survived a certain time, conditional survival captures their future survival probability. We investigated conditional overall and failure-free survival in 473 younger mantle cell lymphoma (MCL) patients from a randomized phase III trial comparing immunochemotherapies R-CHOP and alternating R-CHOP/R-DHAP before autologous transplantation. Using conditional Kaplan-Meier method and Cox regression, we estimated subsequent survival of patients who had survived 1-8 years, considering MIPI, Ki-67, and treatment failure status. Starting at a lower level, R-CHOP patients only showed increasing subsequent survival as they survived longer (5-year conditional survival: 72% and 81% after surviving 1 and 7 years), while R-CHOP/R-DHAP patients had stable future survival over time (77% and 78%). The prognostic value of MIPI diminished after 3 years in R-CHOP patients but remained unchanged after R-CHOP/R-DHAP. Patients with treatment failure had markedly inferior survival compared with those in ongoing remission, regardless of the time survived. The longer patients remained in remission, the longer they would stay free of treatment failures. Our results enable personalized counselling for younger MCL patients by offering dynamic prognosis and underscore the importance of highly effective first-line treatment to improve survival.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jiang L, Dreyling M, Hermine O, et al. Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network. Br J Haematol. 2024. PMID: 39442921. doi:10.1111/bjh.19854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。